What is GLP certification?

GLP certification means a non-clinical research facility has been audited against OECD GLP principles by a national monitoring authority. The audit covers organizational structure, personnel qualifications, facility and equipment validation, standard operating procedures, study plans, raw data handling, archive integrity, and quality assurance independence. GLP applies to safety studies submitted to regulators — not to all research.

Which European countries have the most GLP capacity?

Switzerland and Germany lead by depth (large pharma majors plus integrated CROs). The Nordics carry strong specialty preclinical operators (Denmark, Sweden). Lithuania, Latvia, and Estonia have growing GLP-aligned research and toxicology infrastructure anchored to academic-industrial partnerships. Poland is competitive on cost for outsourced preclinical work.

What is the difference between GLP and GMP?

GLP governs non-clinical research — the safety and toxicology studies done before a drug enters clinical trials. GMP governs the manufacture of medicines for clinical and commercial use. They're sequential in the drug development chain: GLP studies generate the preclinical data that justifies starting a clinical trial; GMP manufacturing produces the actual drug substance and product. A company can hold one, both, or neither — a contract toxicology lab needs GLP; a fill-finish manufacturer needs GMP.

How are GLP-compliant labs verified in this directory?

Every profile is hand-reviewed: GLP claim must be supported by an official source — a national monitoring authority listing, a published GLP certificate, an OECD compliance report, or operator documentation referencing a specific GLP scope. Self-claimed GLP without documentation does not earn the marker.

Compliance filter

GLP biotech companies in Europe — compliance directory

GLP (Good Laboratory Practice) is the OECD-led quality framework that governs non-clinical safety and toxicology studies submitted to drug regulators. A GLP-compliant lab operates under documented procedures for study planning, equipment qualification, raw data integrity, and final-report archiving — required for any preclinical data that supports an IND, CTA, or marketing authorization. This page lists European labs that publicly document GLP capability — preclinical CROs, toxicology operators, bioanalytical labs, and academic research environments — sourced from official certification disclosures, study reports, and operator documentation.

Evidence

Visible records22

Verified22

Countries covered6

Categories7

Avg sources / record0.0

Compliance view

Where is this standard strongest?

Germany (9), Poland (4), Switzerland (4), and Lithuania (3). Top cities: Heidelberg, Germany (5), Vilnius, Lithuania (3), Wroclaw, Poland (3), and Basel, Switzerland (2). Most visible records: Adamed Pharma S.A., Oy Medfiles Ltd., Pure Biologics S.A., and Biomatter.

Compliance view

Which categories carry this standard?

Therapeutics (9), Research (6), Drug discovery (3), and CDMO (1). Latest review: 24 April 2026. Review cycle: April 2026.

Compliance view

Why this standard matters

This page helps separate vague claims from records where the quality or regulatory marker is already visible in public evidence.

Compliance view

Related market brief

A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.

Open related brief

Country breakdown

GLP companies by country

Count of companies with GLP-relevant quality systems, the strongest city in each country, and a sample operator you can open as an entry point.

Country	Companies	Top city	Sample operator
Germany	9	Heidelberg	BioNTech SE
Poland	4	Wroclaw	Bioceltix
Switzerland	4	Basel	Basilea
Lithuania	3	Vilnius	Biomatter
Finland	1	Kuopio	Oy Medfiles Ltd.
Sweden	1	Lund	Camurus

Category breakdown

GLP companies by category

Categories carrying GLP-relevant quality systems, their count, and the strongest sample operator in each.

Category	Companies	Sample operator
Therapeutics	9	BioNTech SE
Research	6	Center for Physical Sciences and Technology
Drug discovery	3	Biomatter
CDMO	1	FyoniBio
CRO	1	Oy Medfiles Ltd.
Manufacturing	1	Adamed Pharma S.A.
Biotech	1	Pure Biologics S.A.

Full list

GLP records

22 compliance records currently match the active filter.

Integrated Polish pharmaceutical manufacturer with API and finished-dose operations, oncology, cardiology, CNS, and respiratory portfolios, and exports to more than 70 countries.

Lead: Piotr KoryckiPresident of the Management Board and Chief Executive Officer
Scale: Commercial pharmaceutical manufacturing

Kuopio full-service CRO owned by WDB Holdings (Japan), covering Phase I-IV clinical trials, bioanalytics, regulatory affairs, pharmacovigilance, and medical device and food studies across the EU and Japan.

Lead: Tuija KeinonenChief Executive Officer
Scale: Full-service CRO operations

Wroclaw antibody and aptamer discovery biotech with PureApta platform, extracorporeal apheresis therapies, and more than thirty specialist laboratories across 1,400 square meters of lab space.

Lead: Filip JelenChief Executive Officer and Co-Founder
Scale: ISO 17025 plus GMP-capable medium-scale production

Vilnius computational-biology company building generative protein-design tools for enzyme engineering and biological product discovery.

Lead: Laurynas KarpusChief Executive Officer and Co-Founder
Scale: AI-enabled protein-discovery platform

Vilnius national research institute spanning materials science, photonics, chemistry, and applied life-science instrumentation.

Lead: Assoc. Prof. Dr. Rimantas RamanauskasGeneral Director
Scale: Large interdisciplinary research institute

Vilnius University flagship life-science campus integrating biochemistry, molecular biology, biotechnology, and training infrastructure.

Lead: Assoc. Prof. Dr. Eugenijus ButkusHead of Center
Scale: University life-science flagship campus

Wroclaw veterinary biologics company developing allogeneic cell therapies and regulated animal-health products.

Lead: Łukasz BzdzionPresident of the Management Board
Scale: Veterinary biologics platform

Wroclaw targeted-protein-degradation company building oncology and immunology programmes around molecular glues and degrader chemistry.

Lead: Michał WalczakChief Executive Officer and Chief Scientific Officer
Scale: Precision-degradation discovery platform

Heidelberg cancer-research flagship integrating oncologic discovery, prevention, translational programmes, and national research infrastructure.

Lead: Prof. Dr. Michael BaumannChairman and Scientific Director
Scale: Large national oncology-research centre

Heidelberg European molecular-biology site linking structural biology, genomics, data, and international training infrastructure into the wider cluster.

Lead: Jan KorbelInterim Head of Site, EMBL Heidelberg
Scale: European molecular-biology flagship site

Berlin biologics-development and bioanalytical platform supporting cell-line development, CMC, and analytical packages for biopharma programmes.

Lead: Philippe UlsemerCo-Founder and Chief Executive Officer
Scale: Integrated biologics-development platform

Ladenburg antibody-drug-conjugate platform focused on amanitin payload technology and oncology pipeline development.

Lead: Dr. Dongzhou Jeffery LiuChief Executive Officer
Scale: Clinical-stage ADC platform

Berlin-Buch biomedical research centre combining disease-biology programmes, technology platforms, and translational partnerships across the German capital region.

Lead: Prof. Dr. Maike SanderChair of the Board and Scientific Director
Scale: Large biomedical research centre

Heidelberg regenerative-medicine company focused on stromal-cell therapies and clinical-stage cell-based products.

Lead: Dr. Christoph GanssPhysician, Chief Executive Officer and Founder
Scale: Clinical-stage regenerative-medicine platform

Basel anti-infectives discovery anchor focused on novel antibacterial programs against multidrug-resistant pathogens.

Lead: Marc GitzingerChief Executive Officer
Scale: Swiss anti-infectives discovery hub

Allschwil discovery and development anchor focused on small-molecule therapeutics across neuroscience, cardiovascular, and metabolic disease platforms.

Lead: Martine ClozelChief Executive Officer
Scale: Swiss discovery and development headquarters

Basel anti-infectives and oncology-development anchor operating a highly specialized therapeutics portfolio with partnered commercial reach.

Lead: David VeitchChief Executive Officer
Scale: Clinical and partnered specialty development

Lausanne oncology and specialty-therapeutics development anchor operating with a clinical-development and partnering model.

Lead: Frédéric LévyChief Executive Officer, Debiopharm International
Scale: Clinical and partnered development

Hamburg discovery and development platform spanning integrated R&D, translational biology, and industrialized biotech partnerships.

Lead: Dr. Christian WojczewskiChief Executive Officer and Chair of the Management Board
Scale: Global research platform

Tübingen mRNA-development and translational-manufacturing anchor with a current executive record and a live RNA platform profile.

Lead: Alexander ZehnderChief Executive Officer
Scale: Clinical and translational development

Lund therapeutic-development anchor built around long-acting drug-delivery technologies and late-stage specialty-pharma execution.

Lead: Fredrik TibergPresident and Chief Executive Officer
Scale: Late-stage and commercial specialty pharma

Mainz mRNA and immunotherapy headquarters coordinating BioNTech's oncology pipeline, manufacturing network, and clinical execution ahead of the planned 2026 launch window.

Lead: Ugur SahinCEO and Co-Founder
Scale: Commercial Phase

FAQ

Frequently asked questions

What is GLP certification?: GLP certification means a non-clinical research facility has been audited against OECD GLP principles by a national monitoring authority. The audit covers organizational structure, personnel qualifications, facility and equipment validation, standard operating procedures, study plans, raw data handling, archive integrity, and quality assurance independence. GLP applies to safety studies submitted to regulators — not to all research.
Which European countries have the most GLP capacity?: Switzerland and Germany lead by depth (large pharma majors plus integrated CROs). The Nordics carry strong specialty preclinical operators (Denmark, Sweden). Lithuania, Latvia, and Estonia have growing GLP-aligned research and toxicology infrastructure anchored to academic-industrial partnerships. Poland is competitive on cost for outsourced preclinical work.
What is the difference between GLP and GMP?: GLP governs non-clinical research — the safety and toxicology studies done before a drug enters clinical trials. GMP governs the manufacture of medicines for clinical and commercial use. They're sequential in the drug development chain: GLP studies generate the preclinical data that justifies starting a clinical trial; GMP manufacturing produces the actual drug substance and product. A company can hold one, both, or neither — a contract toxicology lab needs GLP; a fill-finish manufacturer needs GMP.
How are GLP-compliant labs verified in this directory?: Every profile is hand-reviewed: GLP claim must be supported by an official source — a national monitoring authority listing, a published GLP certificate, an OECD compliance report, or operator documentation referencing a specific GLP scope. Self-claimed GLP without documentation does not earn the marker.

Next step

Read the compliance filter, then move into cities and categories.

This page works best as a starting filter. For deeper comparison, use city, category, and methodology pages.

Open strongest city Open strongest category Open methodology Suggest a company

GLP biotech companies in Europe — compliance directory

Where is this standard strongest?

Which categories carry this standard?

Why this standard matters

Related market brief

GLP companies by country

GLP companies by category

GLP records

Adamed Pharma S.A.

Oy Medfiles Ltd.

Pure Biologics S.A.

Biomatter

Center for Physical Sciences and Technology

Vilnius University Life Sciences Center

Bioceltix

Captor Therapeutics

German Cancer Research Center

EMBL Heidelberg

FyoniBio

Heidelberg Pharma

Max Delbruck Center Berlin-Buch

RHEACELL

BioVersys

Idorsia

Basilea

Debiopharm

Evotec

CureVac

Camurus

BioNTech SE

Frequently asked questions

Read the compliance filter, then move into cities and categories.